PCAsso Diagnostics LLC is a New Jersey diagnostics company developing novel and disruptive diagnostic technology, PCA. PCA is an angiography contrast agent technology that will allow stratification of disease severity based on the degree of vascular pathology. PCA will be used initially for retinal disease (diabetic retinopathy, AMD, uveitis and others) and is expected to produce a paradigm shift in the management of these diseases.